Miconal

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Miconal

What is Miconal? (Miconazole Nitrate)

Miconal is a common designation for a medicine whose active ingredient is Miconazole Nitrate, a synthetic compound classified as an azole antifungal. This medication is fundamentally designed to inhibit the growth of the various fungal and yeast organisms responsible for common superficial infections. As an imidazole derivative, its purpose is to directly address the presence of the fungal pathogen.


Quick Facts: Miconazole Nitrate

Property Description
Active ingredient Miconazole Nitrate
Forms Cream, Powder, Suppository, Gel, Tablet
Pharmacological class Azole Antifungal
Common use Halts the growth of fungi and yeasts
Origin Synthetic (Imidazole derivative)

What Type of Medicine is Miconal and Its Active Composition?

Miconal is an azole antifungal that operates as a single-ingredient product whose efficacy relies entirely on the compound Miconazole Nitrate. Chemically, miconazole (the official non-proprietary name, or INN) is a synthetic compound that is prepared as a nitrate salt to ensure stability and bioavailability in pharmaceutical preparations. The medication belongs to the broader pharmacological class of antifungals, distinguishing it from antibacterial or antiviral agents by its specific cellular targets within fungal organisms. This imidazole class is effective against a wide range of common fungal species.

The formulation typically includes the active ingredient combined with a suitable inert base or vehicle, such as a cream excipient, a powder, or an ointment. This base is necessary to deliver the active Miconazole Nitrate to the required site of action.


Versatile Forms and General Antifungal Purpose

Miconal is manufactured in diverse dosage forms that allow for localized application, including a cream, a specialized powder, and a vaginal suppository, among others, supporting topical and localized routes of administration. The availability of multiple preparations allows patients to utilize the form that is most appropriate for their specific location of infection. For instance, the powder form is often positioned for treating fungal issues that thrive in moist areas, differentiating its application from the cream formulations.

The general purpose of Miconal is to provide a broad-spectrum agent that serves to stop the proliferation of various pathogenic fungi and yeasts. Miconazole works by interfering with the fungi's essential ability to produce ergosterol, which is vital for the fungal cell membrane. This mechanism offers the benefit of halting fungal growth, which is necessary to resolve the infection and its associated discomfort.

What side effects are possible with Miconal?

Possible Side Effects and Safety Information

The safety profile for Miconal (Miconazole Nitrate) is structured by regulatory authorities around potential local reactions and rare, serious systemic events. The majority of documented adverse reactions relate to the Skin and Subcutaneous Tissue Disorders and General Disorders at the Administration Site.

Frequency-Classified Adverse Reactions

Adverse reactions are classified according to regulatory standards based on observed incidence:

  • Uncommon (ge 1/1,000 to <1/100): Local skin reactions, including a skin burning sensation, pruritus (itching), irritation, and warmth at the application site. These effects are often noted to occur at the start of treatment.
  • Not Known (Cannot be estimated from available data): More severe reactions like urticaria (hives), contact dermatitis, rash, and erythema (redness) have been reported via post-marketing surveillance.

Serious Safety Considerations

Official regulatory documents note the potential for rare but serious Immune System Disorders. These include severe hypersensitivity reactions such as anaphylaxis and angioedema. Miconal is formally contraindicated in individuals with a known hypersensitivity to miconazole, other azole derivatives, or any of the product's excipients.

Interaction and Specific Safety Notes

Although systemic absorption is typically minimal with topical use, a safety concern is documented regarding the potential for Miconazole to enhance the effect of oral anticoagulants, such as warfarin. Additionally, specific formulations may contain excipients that can weaken latex in barrier contraceptives like condoms or diaphragms. The official labeling for certain products also includes a warning that product residue on fabrics may pose a fire hazard.

Overdose and Emergency Response

Miconal (Miconazole Nitrate) overdose information is primarily documented in the context of accidental oral ingestion of the product, as systemic absorption from routine topical application is limited. The official regulatory profile identifies the primary manifestations associated with high systemic overexposure as gastrointestinal effects, including nausea, vomiting, and diarrhea. For cases of excessive local application, the clinical presentation is generally limited to localized skin irritation, which resolves upon product discontinuation.

In the event of accidental ingestion of large quantities, government regulatory agencies explicitly mandate seeking immediate medical attention or contacting a Poison Control Center right away. The official management approach for overexposure is defined as symptomatic and supportive treatment. Specific procedural steps, such as gastric lavage or the administration of activated charcoal, may be initiated by healthcare professionals following documented significant oral intake. The regulatory labeling confirms that no specific antidote is known for Miconazole Nitrate overdose. Therefore, the regulatory requirement is for immediate external medical consultation following any significant oral exposure.

Therapeutic Uses of Miconal

What Miconal Treats: Main Uses and Benefits

Miconal is applied across domains where additional symptomatic support is needed, typically in conditions characterized by periods of heightened symptoms. It contributes to easing the overall symptom load and supports general well-being during symptomatic phases.

Managing Acute Symptomatic Discomfort

Miconal is considered relevant in clinical settings that involve acute or unstable symptom patterns, particularly for symptoms related to physical discomfort. It helps address symptom clusters that may become intense or disruptive, and assists with maintaining functional stability.


Quick Fact: Relevant for Easing Symptoms of Irritation

Addressing Episodic and Fluctuating Symptoms

This medication is commonly used across conditions involving episodic or fluctuating manifestations and where symptoms may intensify temporarily. It supports patients during episodes of heightened discomfort and may help patients cope more steadily with symptom fluctuations.

Regulatory References

  1. Health Canada's official labelling standard

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Miconal — official regulatory information


Eligibility Scope

Populations for whom use is allowed (as stated in label): General adults and older adults for topical use, as no specific age-related restrictions are formally required.

Populations for whom use is not recommended (if applicable): Use is not recommended for children under 2 years of age unless directed by a health professional. Safety and efficacy are not established in infants under 4 weeks of age for certain specific formulations.

Populations for whom use is contraindicated: Individuals with known hypersensitivity or allergy to Miconazole, other imidazole antifungals, or any component of the product.

Age-related eligibility rules: Use is restricted below 2 years for topical forms; safety is not established below 4 weeks for certain infant forms.

Condition-specific eligibility rules: No limitations are formally documented for hepatic or renal impairment in topical or vaginal labels.

Pregnancy and lactation eligibility status (if explicitly documented): Status is Conditional Use; consultation with a health professional is required before use during pregnancy or lactation.

Eligibility-related restrictions: Conditional use requires professional consultation for frequent infections and for patients with diabetes or a weakened immune system, as these conditions may necessitate specialized management.


Eligibility Classifications (High-Level)

Eligibility severity classification (as defined in official documents): Contraindicated; Not Recommended; Conditional Use.

Regulatory basis (EMA / FDA / etc.): FDA DailyMed / Prescribing Information.

Eligibility-context constraints (as defined in official documents): Age-group specific limitations; Reproductive status requiring professional consultation; Comorbidity presence requiring professional consultation.


Resulting Eligibility Structure

Official eligibility statements:

  • Miconal is contraindicated in patients with a known hypersensitivity to the drug or its components.
  • Use is not recommended in children under 2 years of age unless directed by a health professional.
  • Consultation with a health professional is required before use during pregnancy or lactation.
  • Patients with diabetes or a weakened immune system must consult a doctor if they have frequent infections.

Connection to the overall eligibility profile (2–4 sentences): Official regulatory documents define who can and cannot use Miconal through an Absolute Contraindication based on hypersensitivity. Eligibility is further structured by Age-Based Restrictions, limiting use in specific pediatric groups, and by Conditional Use mandates that require consultation for pregnant/lactating populations and for patients with specific comorbidities linked to recurrent infection.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Miconal (Miconazole Nitrate) is documented to interact with other medicines primarily through a pharmacokinetic interaction. This is based on its function as a documented inhibitor of the metabolic enzymes CYP3A4 and CYP2C9, as stated in regulatory prescribing information. This inhibition can lead to significantly increased plasma concentrations of co-administered substances.


Contraindicated and Restricted Combinations

Formal regulatory documentation strictly identifies certain medicinal products as contraindicated for co-administration. These substances include Pimozide, Ergot Alkaloids (such as Dihydroergotamine and Ergotamine), and specific Statins (including Lovastatin and Simvastatin). Combining Miconal with these medicines is prohibited due to the risk of severely enhanced exposure.


Other Clinically Significant Interactions

For other co-administered drugs, Miconal may cause an officially documented enhancement of effect. This includes an enhanced anticoagulant effect with Vitamin K Antagonists (e.g., Warfarin), requiring mandated close monitoring of the patient's International Normalized Ratio (INR). Exposure of other medicines, such as Phenytoin and various Oral Hypoglycemics (e.g., Glibenclamide), is also documented to increase, requiring caution.

Additionally, the excipient base of Miconal vaginal formulations may cause a pharmacodynamic interaction by compromising the structural integrity of latex-containing contraceptive devices like condoms or diaphragms.

Mechanism of Action

Mechanism of Action: Miconazole Pharmacodynamics

Miconal (Miconazole) exerts its effect by acting as an inhibitor of a core fungal enzymatic pathway. The drug's primary molecular target is the fungal enzyme 14alpha-lanosterol demethylase (CYP51), a critical component of the cytochrome P450 system unique to fungi. The molecular interaction occurs when Miconazole binds directly to the heme iron of this enzyme, thereby preventing its catalytic function and blocking the synthesis of ergosterol, the essential building block of the fungal cell membrane.

This inhibition initiates a destructive downstream cascade. The resulting deficiency in ergosterol leads to the accumulation of toxic, methylated sterol intermediates. These abnormal sterols integrate into the cell membrane, severely compromising its physical structure, fluidity, and selective permeability. This damage causes the leakage of vital intracellular components, resulting in fungal cell lysis and the cessation of cellular viability, which constitutes the final mechanistic consequence.

Dosage and Administration Information

Official Miconal Administration Guidelines

Miconal, the formulation containing Miconazole Nitrate, is administered through several routes, with specific dosing and duration protocols tied to each product form.

Administration Route Standard Regimen Examples Course Duration
Intravaginal (Suppository/Cream) 1200 mg once daily at bedtime; 200 mg once daily at bedtime; 2% cream once daily at bedtime. Fixed courses of 1, 3, or 7 consecutive days.
Topical (Cream/Powder) A thin layer of 2% preparation applied to the affected area. Twice daily application for 2 to 4 weeks, with application continued for at least one week after symptoms resolve.
Buccal (Tablet) One 50 mg tablet applied to the upper gum. Once daily for 14 consecutive days.

For topical application, the skin must be cleaned and dried thoroughly before the thin layer of medicine is gently rubbed in. Occlusive dressings are generally not advised. For the buccal tablet, the dose is applied to the upper gum after brushing in the morning; the tablet must not be crushed, chewed, or swallowed. Subsequent daily buccal applications should be made to alternate sides of the mouth.

Use of intravaginal products is typically restricted to adults and children 12 years of age and older, while topical forms are generally used in children 2 years of age and older. If a dose is missed, it should be applied as soon as possible, unless it is almost time for the next scheduled dose, in which case the missed dose is skipped, and the regular schedule is resumed.

Recent Clinical Evidence

Research evidence / Overview of studies for Miconal

Evidence for Vulvovaginal Candidiasis (Vaginal Yeast Infection) Research

Miconal was studied for the management of vaginal yeast infections in numerous controlled trials. Researchers have primarily used short-term Randomized Controlled Trials (RCTs) that focus on adult, non-pregnant women with confirmed infections. The main outcomes measured in these studies included the tracking of mycological status and the evolution of physical signs and outcomes linked to inflammatory or irritative states. The most comprehensive outcome measured in the trials was classified as Therapeutic Cure, which combines both the absence of the fungus and patient-reported outcomes describing perceived discomfort.

However, the existing studies provide limited insight into long-term outcomes. Data on patterns of recurrence or relapse over many months or years are not fully established. Furthermore, while general adult populations was studied for this condition, data for certain groups, such as pregnant women, remain insufficient and often rely on observational research rather than formal clinical trials.

Evidence for Cutaneous Candidiasis and Dermatophytoses (Skin Fungal Infections) Research

For skin fungal conditions, research has been studied for Miconal formulations in many RCTs. These studies were conducted in various populations, ranging from adults and adolescents to specific pediatric groups, such as infants with secondary complications from diaper rash. Researchers defined the measured endpoints by classifying outcomes such as Overall Clinical Endpoint (a composite of mycological and physical sign status), and monitored the changes in outcomes describing episodic or acute changes like redness, scaling, and itching.

Gaps in the Evidence and Areas of Uncertainty

Overall, the research contributes to understanding symptom patterns for the approved uses, but limitations exist. A major gap is the lack of extensive, long-term data; there is limited information for long-term outcomes because follow-up durations were limited in many primary trials. Comparative evidence for certain complex or chronic fungal infections is limited, and the subgroup findings are uncertain when applied to patients outside of those precisely defined in the trials.

Key Studies & References

  1. Miconazole Nitrate: Labeling Standards - Non-prescription Drugs (Health Canada)
  2. Miconazole Nitrate Topical: Full Prescribing Information and Safety (FDA DailyMed)

Frequently Asked Questions (FAQ)

Common questions about Miconal (FAQ)


Q: What happens if I miss a scheduled dose of Miconal?

Official administration guidelines state that if a dose is forgotten, it should be applied as soon as it is remembered. However, if it is almost time for the next scheduled dose, the regulatory instruction is to skip the missed dose and resume the regular schedule. Referencing the patient information specific to your Miconal form is recommended.


Q: Can Miconal be taken alongside pain relievers like ibuprofen or acetaminophen?

Official documents that list interactions primarily focus on prescription drugs with known risks. While Miconal's topical and vaginal forms usually have minimal systemic absorption, general regulatory practice indicates that a healthcare professional should be informed about all medications, including over-the-counter pain relievers, due to the potential for interactions.


Q: Can Miconal interact with hormonal birth control pills?

Regulatory information indicates that Miconazole can potentially alter the levels of certain hormones found in some oral contraceptives, such as ethinyl estradiol. If hormonal birth control is being used, the combination may necessitate professional monitoring.


Q: What does the official drug information say about using Miconal while breastfeeding?

Miconal has a Conditional Use status during lactation, which indicates that consultation with a healthcare professional is necessary before use. Official information from sources like LactMed indicates that, due to the minimal systemic absorption from topical or vaginal application, the active ingredient is unlikely to cause adverse effects on a breastfed infant.


Q: Is it necessary to finish the entire course of Miconal even if symptoms improve?

Official directions for use consistently instruct patients to continue using the application for the full prescribed course. This measure is intended to support the complete resolution of the infection and is consistent with the goal of preventing recurrence.


Q: Can Miconal be crushed or split if it is a tablet?

Regulatory instructions for the buccal tablet form specifically state that the tablet must not be crushed, chewed, or swallowed. If your prescription is for a different tablet type, preparation instructions should be confirmed with the specific product’s labeling.


Q: What is the official recommended action if a side effect is experienced?

Patients are officially instructed to contact a doctor or healthcare provider if side effects are concerning, if they do not go away, or if they notice signs of a severe reaction. If accidental swallowing is suspected, contacting a doctor or poison control center right away is the instruction provided.


Q: What are the main ingredients in Miconal besides the active substance?

Miconal products contain the active ingredient, Miconazole Nitrate, combined with inactive ingredients called excipients. Regulatory documents require that all excipients, such as petrolatum, mineral oil, or benzoic acid, be listed, as they form the necessary base for the cream, powder, or other forms.


Q: What does the 'What Miconal treats' section cover regarding its benefits?

Official regulatory labeling indicates Miconal is used in the treatment of common fungal infections. This typically includes most cases of athlete's foot (tinea pedis), jock itch (tinea cruris), and ringworm (tinea corporis).


Q: What is the main difference between Miconal and over-the-counter treatments for the same condition?

Miconal is a designation for Miconazole Nitrate, which is classified as an azole antifungal. The substance is widely available in both prescription and over-the-counter (OTC) formulations, meaning the main difference may lie in the strength or the specific formulation (e.g., cream versus a suppository) rather than the active ingredient itself.


Q: Does Miconal contain any common allergens like gluten or lactose?

Official product labels are required to list all inactive ingredients, or excipients. The presence of specific common allergens like gluten or lactose is not universally stated, so the excipient list for your specific formulation should be checked to confirm its contents.


Q: Is Miconal the same as [Name of similar popular drug]?

Miconal is an imidazole antifungal, and any comparison to another drug requires checking its official regulatory classification. The products are considered the same only if they contain the exact same active substance (Miconazole Nitrate) and are classified in the same way.


Q: How long after starting Miconal should a person expect to feel a change?

Official information indicates that the time until a change is experienced can vary. However, some symptom improvement has been noted within one day of use, with the full therapeutic effect intended to be achieved upon completion of the prescribed course.


Q: Are there any foods or drinks that should be avoided while taking Miconal?

Because topical and vaginal forms of Miconal have minimal systemic absorption into the bloodstream, they typically have low concern for food or drink interactions. Nonetheless, discussion regarding the consumption of food, alcohol, or tobacco with a healthcare professional is recommended.


Q: Can Miconal be used by older adults?

For topical Miconal, regulatory documents state there is no specific information comparing use in the elderly with use in other age groups. The medicine is generally not expected to cause different side effects or problems in older adults than in younger adults.


Q: Is it common to feel slightly nauseous when first starting Miconal?

Yes, regulatory documents list nausea and vomiting as potential side effects that have been reported with Miconal use, particularly when using vaginal formulations. These effects are typically expected to be temporary.


Q: How quickly does Miconal start working once it's in the body?

Clinical summaries indicate that Miconal’s antifungal mechanism begins upon application. While the full therapeutic effect is intended to be achieved upon completion of the course, official information notes that some patients report initial symptom improvement within one day.


Q: Is Miconal known to interact with commonly used vitamins or supplements?

Official drug information advises patients to inform a healthcare professional about all medicines used, including herbal or vitamin supplements, as potential interactions exist. This caution is necessary before use.


Q: What is the purpose of the different strengths of Miconal, if available?

Regulatory documents indicate different strengths or dosage forms (such as 200 mg versus 1200 mg vaginal inserts) are used to accommodate various fixed-course durations. This allows for the selection of different treatment regimens, such as a 1-day, 3-day, or 7-day course.


Q: Does Miconal cause drowsiness or affect the ability to drive?

Drowsiness is generally not listed as a common side effect for the topical or vaginal forms of Miconal. However, general safety guidance advises that if any side effects are experienced that could impair the ability to operate machinery, avoiding driving or operating machinery is the general safety guidance.


Q: What should be done if an accidental overdose of Miconal is suspected?

All official product labels warn that the drug may cause harm if swallowed. If accidental swallowing is suspected, contacting a doctor or poison control center right away is the instruction provided.


Q: Is Miconal safe to use if a person has a history of liver problems?

Miconazole is primarily metabolized (broken down) by the liver, as regulatory notes state. Therefore, for patients with known liver disease, the therapy should be administered cautiously, and a healthcare professional is required to determine the appropriateness of use.


Q: Are the side effects of Miconal permanent or do they stop when the medicine is stopped?

The majority of documented side effects for Miconal are local reactions at the application site, such as burning or itching. These effects are typically noted to resolve upon discontinuation of the medicine after the treatment course is complete.


Q: Does regulatory research show Miconal is effective in children?

Official research documents efficacy in certain pediatric groups for specific skin conditions, such as the use of topical creams in infants with diaper dermatitis. However, its use is officially restricted or not recommended in children under 2 years of age unless directed by a healthcare professional.


Q: Is there any research that discusses the long-term effects of taking Miconal?

The official research summary for Miconal explicitly states that a major gap in the evidence is the lack of extensive, long-term data. Many primary clinical trials had follow-up durations that were limited, meaning long-term outcomes are not fully established.


Q: Can Miconal cause skin sensitivity to sunlight?

While regulatory safety sheets do not typically list photosensitivity (sensitivity to sunlight) as a common hazard for Miconazole Nitrate, they do contain general warnings about the potential for the drug to cause skin irritation or allergic reaction on the skin.


Q: Is Miconal a narcotic or a controlled substance?

No. Official drug classifications confirm Miconal (Miconazole) is an azole antifungal. It is not a controlled medication or a narcotic as defined by government regulatory agencies like the DEA.


Q: Is Miconal a long-term or short-term treatment?

Miconal is designated for fixed-course durations that are typically short-term. For example, vaginal products are often prescribed for 1, 3, or 7 days, and topical creams for 2 to 4 weeks, defining it as an acute treatment for fungal infections.


Q: Does the efficacy of Miconal depend on when it is taken during the day?

Yes, for certain formulations. Specific administration times are noted in the patient information, such as the use of buccal tablets after brushing in the morning or vaginal products at bedtime. This indicates the time of day can be relevant to the prescribed regimen.


Q: Is it normal to have mild headaches when starting Miconal?

Yes, regulatory documents list headache as a potential side effect that has been reported, particularly when using vaginal product formulations.


Q: Do any official documents discuss Miconal's potential impact on fertility?

Official documents summarize data from animal studies, which assessed reproductive health. These studies found that Miconazole had no adverse effect on fertility in test animals, though this information is primarily used by regulators to assess potential human risk.


Q: Is Miconal available without a prescription in any countries?

Official regulatory classifications confirm that Miconal (Miconazole Nitrate) is approved as both an Over-The-Counter (OTC) drug and a prescription drug. Its availability status depends entirely on the specific country and the formulation's strength.

How should Miconal be stored and disposed of?

The storage and disposal of Miconal (Miconazole Nitrate) are governed by strict regulatory standards to ensure product stability and safety.

Storage Requirements

Miconal must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). The medicine must be protected from freezing, excessive heat, moisture, and light. It is mandatory to keep the product in its original container and ensure the container is tightly closed when not in use. All forms of Miconal must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Miconal should preferably be disposed of through a drug take-back program. If a take-back option is unavailable, the medicine should be mixed with an undesirable substance, sealed in a bag or container, and placed in the household trash. Aerosol formulations must not be punctured or incinerated.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Miconal found in:

A-Z Index: